By Fineline Cube Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary clinical data for LM-299/MK-2010, a PD-1/VEGF bispecific antibody (BsAb) co-developed by its subsidiary LaNova Medicines Ltd and Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate encouraging antitumor activity and a manageable safety profile in non-small cell lung cancer (NSCLC) patients, validating MSD’s $3.3 billion licensing investment made in 2024.
Deal Structure & Strategic Context
| Item | Detail |
|---|---|
| Lead Developer | LaNova Medicines Ltd (subsidiary of Sino Biopharmaceutical) |
| Global Partner | Merck, Sharp & Dohme Inc. (NYSE: MRK) |
| Licensing Deal | $3.3 billion agreement (2024) |
| Rights Granted | Exclusive global development, manufacturing, and commercialization rights to LM-299/MK-2010 |
| Acquisition Timeline | Sino Bio acquired LaNova in July 2025, securing the product pipeline |
| Clinical Presentation | AACR Annual Meeting 2026 |
Clinical Trial Design & Patient Population
- Study Phase: Phase I/II clinical trial
- Total Enrolled: 112 patients receiving MK-2010/LM-299
- Dose-Escalation Cohort: 40 patients
- NSCLC Expansion Cohort: 72 patients
- Dosing Regimens: 20 mg/kg Q3W and 30 mg/kg Q3W groups
- Patient Population: Treatment-naïve NSCLC patients in expansion cohort
Safety Profile – Manageable Toxicity Profile
| Safety Parameter | Result |
|---|---|
| Grade 5 TRAEs | None observed |
| Treatment Discontinuations | 1 patient (dose-escalation cohort) |
| Grade 3-4 TRAEs (NSCLC cohort) | 17–27% incidence |
| Treatment-Related Deaths | None reported |
| VEGF Inhibitor Toxicities | Predominantly ≤ grade 3, manageable |
The bispecific antibody demonstrated a favorable safety profile consistent with established PD-1 and VEGF inhibitor classes, with no unexpected safety signals identified.
Efficacy Results – Promising Antitumor Activity
| Efficacy Endpoint | 20 mg/kg Q3W | 30 mg/kg Q3W |
|---|---|---|
| Unconfirmed ORR (treatment-naïve NSCLC) | 55% | 44% |
| Pharmacokinetic Half-life | 9.5–12.6 days (mean across cohorts) |
The 55% objective response rate in the 20 mg/kg cohort represents competitive efficacy compared to existing PD-1 monotherapies and combination regimens in first-line NSCLC settings.
Market Implications & Competitive Positioning
- NSCLC Market Opportunity: Global NSCLC therapeutics market projected to reach $45 billion by 2030, with bispecific antibodies emerging as a key growth segment.
- Competitive Landscape: LM-299/MK-2010 competes with other PD-1/VEGF bispecifics including Roche’s faricimab and emerging candidates from AstraZeneca and BeiGene.
- Revenue Potential: Given MSD’s $3.3 billion upfront commitment and global rights, peak sales projections could exceed $2 billion annually if Phase III confirms current efficacy signals.
- Strategic Value for Sino Bio: The acquisition of LaNova has proven prescient, providing Sino Biopharmaceutical with significant milestone payments and royalty streams from one of the most promising bispecific programs in oncology.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for LM-299/MK-2010. Actual results may differ due to risks including Phase III trial outcomes, regulatory decisions, competitive dynamics, and market adoption rates.-Fineline Info & Tech